Codexis, Inc. (CDXS)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Codexis, Inc. currently loses $80.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 5
in 11 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Codexis beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported August 11, 2026, as revenue of $14.9 million topped the $13.8 million estimate (+7.9%) even while slipping 2.7% year over year from about $15.3 million. EPS of -$0.13 also topped the -$0.14 estimate by $0.01 and improved 18.8% from -$0.16 a year ago, alongside net income of roughly -$12.0 million, a 9.5% improvement from about -$13.3 million. Profitability was supported by gross profit of around $11.4 million with gross margin at roughly 77%, while operating income was about -$11.2 million and operating margin was -75.3%. Cash generation remained negative, with negative operating cash flow of about $9.6 million. For the next period, consensus calls for EPS of -$0.09 on revenue of $18.6 million.
Next report — what to expect
Codexis, Inc. (CDXS) reports earnings on November 5, 2026. Wall Street is looking for consensus EPS of -$0.09 on revenue of $18.7 million. For trailing context, revenue declined -2.7% year over year last quarter. CDXS has beaten EPS in 4 of its 8 most recent quarters.
About Codexis, Inc.
Codexis, Inc. develops enzyme engineering and biocatalysis tools for the biotechnology end of healthcare and trades on the NASDAQ as CDXS. In FY2025, the company recorded $70.4 million in revenue from products and services used by pharmaceutical manufacturers, including advanced biocatalyst products, screening tools, and protein engineering work.
Today's Snapshot
CDXS closed 2.3% lower at 1.28, in line with a weaker sector. Shares changed hands at about two-thirds of its usual level.
Trading Volume
Below 10d avg (906.5K)
542.2K
vs S&P 500 Today
Underperforming Market
-1.77%
Updated: October 23, 2026 at 20:26 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$1.31 - $1.73Sell
- RSI (14)43.77Neutral
- Stochastic %K (14, 3, 3)34.72Neutral
- MACD Level (12, 26)-0.04Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.